文献速递慢性肾脏病肾血管病与高血压

慢性肾脏病患者的糖尿病管理:2022核心教程

Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022.
PubMed 文献 · Am J Kidney Dis · 2021-09-30

糖尿病是美国及全球肾衰竭最常见病因,慢性肾脏病进一步增加心血管疾病风险。需个体化血糖目标,避免低血糖,并随CKD进展调整药物剂量;胰岛素和磺脲类增加低血糖风险,部分GLP-1受体激动剂和多数SGLT2抑制剂可降低心血管及肾脏结局风险。

要点

  • 个体化血糖目标,平衡并发症预防与低血糖风险。
  • CKD进展时需调整降糖药物剂量,注意药物特性。
  • 优先考虑具有心肾保护证据的降糖药如SGLT2抑制剂。

核心结论

  • CKD患者糖尿病管理需个体化血糖目标,随CKD进展调整药物,优先选用具有心肾保护作用的药物。

主要发现

  • 心血管疾病是糖尿病患者发病和死亡的主要原因,CKD进一步增加心血管风险。
  • CKD改变血糖与糖化血红蛋白等长期控制指标的关系。
  • 胰岛素和磺脲类增加低血糖风险;部分GLP-1受体激动剂降低心血管结局风险;多数SGLT2抑制剂降低CKD和心血管结局风险。

临床怎么用

  • 根据CKD分期个体化设定血糖目标,避免低血糖。
  • 定期评估并调整降糖药物剂量,注意药物在CKD中的特性。
  • 对CKD患者优先考虑具有心肾保护证据的降糖药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The most common cause of kidney failure in the United States and across the world is diabetes mellitus (DM). Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in persons with diabetes, and chronic kidney disease (CKD) further increases overall CVD risk. It is important to individualize glycemic targets for patients to maintain glucose levels that will reduce the development and progression of complications while avoiding hypoglycemia. CKD alters the relationship of glucose levels to measures of long-term control, such as hemoglobin A1c. Medications used to treat DM may need dose adjustments as CKD progresses. Some medications have particular characteristics in patients with CKD. Insulin and sulfonylureas increase the risk of hypoglycemia, some glucagon-like peptide 1 receptor agonists reduce the risk of CVD outcomes, and most sodium/glucose cotransporter 2 inhibitors reduce the risk of CKD and CVD outcomes. Therefore, for the individual patient, changes in medication types and doses may need constant attention as CKD progresses.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Hahr AJ, Molitch ME. Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022. Am J Kidney Dis. 2021. PMID: 34600745. doi:10.1053/j.ajkd.2021.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。